3-Cyclobutyl-2-({[(9H-fluoren-9-YL)methoxy]carbonyl}amino)propanoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 3-Cyclobutyl-2-({[(9H-fluoren-9-YL)methoxy]carbonyl}amino)propanoic acid
• 英文别名: 3-cyclobutyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
• 化学式: C₂₂H₂₃NO₄
• 分子量: 365.429
• InChiKey: FOJRBUNCWCPLNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Rink amide resin 、 N-BOC-S-trityl-L-cysteine 、 3-Cyclobutyl-2-({[(9H-fluoren-9-YL)methoxy]carbonyl}amino)propanoic acid 、 Fmoc-Gln(Trt) 、 Fmoc-Lys(Mtt)-OH 、 N-芴甲氧羰基-DL-正亮氨酸 生成
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE
  申请人：JCR Pharmaceuticals Co., Ltd.

  公开号：EP4108676A1

  公开（公告）日：2022-12-28

  [Problem] To provide a peptide, etc., capable of passing through the blood-brain barrier (BBB) by binding to a human transferrin receptor (hTfR). [Solution] A peptide, etc., having the amino acid sequence shown in SEQ ID NO: 1 (Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Ser-Cys) or an amino acid sequence having substitutions, deletions, additions, and/or insertions of 1 to 10 amino acid residues (inclusive) in the amino acid sequence shown in SEQ ID NO: 1.

  [问题]提供一种能够通过与人转铁蛋白受体（hTfR）结合而通过血脑屏障（BBB）的多肽等。[解决方案]一种多肽等，具有 SEQ ID NO: 1 所示的氨基酸序列（Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-SEr-Cys）或在 SEQ ID NO: 1 所示的氨基酸序列中具有 1 至 10 个氨基酸残基（含）的取代、缺失、添加和/或插入的氨基酸序列。
• BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2
  申请人：BicycleRD Limited

  公开号：US20200338203A1

  公开（公告）日：2020-10-29

  The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and dmg conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).